Genetic polymorphisms of metabolic enzymes CYP1A1, CYP2D6, GSTM1 and GSTT1 and leukemia susceptibility

European Journal of Cancer Prevention

Volumn 17, Issue 3, 2008, Pages 251-258

  Chen, Han Chun ^a   Hu, Wei Xin ^a   Liu, Qing Xia ^a   Li, Wen Kai ^a   Chen, Fang Zhi ^b   Rao, Zhou Zhou ^b   Liu, Xin Fa ^a   Luo, Ya Ping ^a   Cao, Yan Fei ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CYP1A1; CYP2D6; Genetic polymorphism; GSTM1; GSTT1; Leukemia susceptibility

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 2D6; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BIOTRANSFORMATION; CANCER SUSCEPTIBILITY; CHILD; CHINA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2D6; DNA MUTATIONAL ANALYSIS; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; LEUKEMIA; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 42249095950     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e3282b72093     Document Type: Article

References (61)

1. Agundez JA (2004). Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab 5:211-224.
2. Armstrong M, Fairbrother K, Idle JR, Daly AK (1994). The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics 4:73-81.
3. Aydin M, Hatirnaz O, Erensoy N, Ozbek U (2005). CYP2D6 and CYP1A1 mutations in the Turkish population. Cell Biochem Funct 23:133-135.
4. Aydin-Sayitoglu M, Hatirnaz O, Erensoy N, Ozbek U (2006). Role of CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias. Am J Hematol 81:162-170.
5. Bartsch H, Hietanen E (1996). The role of individual susceptibility in cancer burden related to environmental exposure. Environ Health Perspect 104 (Suppl 3):569-577.
6. Brockmoller J, Cascorbi I, Kerb R, Roots I (1996). Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 56:3915-3925.
7. Cao W, Cai L, Rao JY, Pantuck A, Lu ML, Dalbagni G, et al. (2005). Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma. Cancer 104:2400-2408.
8. Chen CL, Liu Q, Relling MV (1996). Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics 6:187-191.
9. Chen CL, Liu Q, Pui CH, Rivera GK, Sandlund JT, Ribeiro R, et al. (1997). Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood 89:1701-1707.
10. Chen HC, Cao YF, Hu WX, Liu XF, Liu QX, Zhang J, Liu J (2006). Genetic polymorphisms of phase II metabolic enzymes and lung cancer susceptibility in a population of Central South China. Dis Markers 22:141-152.
11. Clavel J, Bellec S, Rebouissou S, Menegaux F, Feunteun J, Bonaiti-Pellie C, et al. (2005). Childhood leukaemia, polymorphisms of metabolism enzyme genes, and interactions with maternal tobacco, coffee and alcohol consumption during pregnancy. Eur J Cancer Prev 14:531-540.
12. Crump C, Chen C, Appelbaum FR, Kopecky KJ, Schwartz SM, Willman CL, et al. (2000). Glutathione S-transferase theta 1 gene deletion and risk of acute myeloid leukemia. Cancer Epidemiol Biomarkers Prev 9:457-460.
13. Dahl ML, Yue QY, Roh HK, Johansson I, Sawe J, Sjoqvist F, Bertilsson L (1995). Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 5:159-164.
14. Dalhoff K, Buus Jensen K, Enghusen Poulsen H (2005). Cancer and molecular biomarkers of phase 2. Methods Enzymol 400:618-627.
15. D'Alo F, Voso MT, Guidi F, Massini G, Scardocci A, Sica S, et al. (2004). Polymorphisms of CYP1A1 and glutathione S-transferase and susceptibility to adult acute myeloid leukemia. Haematologica 89:664-670.
16. Fragoso JM, Juarez-Cedillo T, Hernandez-Pacheco G, Ramirez E, Zuniga J, Izaguirre R, et al. (2005). Cytochrome P4501A1 polymorphisms in the Amerindian and Mestizo populations of Mexico. Cell Biochem Funct 23:189-193.
17. Gallegos-Arreola MP, Batista-Gonzalez CM, Delgado-Lamas JL, Figuera LE, Puebla-Perez AM, Arnaud-Lopez L (2004). Cytochrome P4501A1 polymorphism is associated with susceptibility to acute lymphoblastic leukemia in adult Mexican patients. Blood Cells Mol Dis 33:326-329.
18. Gao Y, Zhang Q (1999). Polymorphisms of the GSTM1 and CYP2D6 genes associated with susceptibility to lung cancer in Chinese. Mutat Res 444:441-449.
19. Garte S, Taioli E, Crosti F, Sainati L, Barisone E, Luciani M, et al. (2000). Deletion of parental GST genes as a possible susceptibility factor in the etiology of infant leukemia. Leuk Res 24:971-974.
20. Gomes L, Lemos MC, Paiva I, Ribeiro C, Carvalheiro M, Regateiro FJ (2005). CYP2D6 genetic polymorphisms are associated with susceptibility to pituitary tumors. Acta Med Port 18:339-343.
21. Harris CC (1989). Interindividual variation among humans in carcinogen metabolism, DNA adduct formation and DNA repair. Carcinogenesis 10:1563-1566.
22. Hatagima A (2002). Genetic polymorphisms and metabolism of endocrine disruptors in cancer susceptibility. Cad Saude Publica 18:357-377.
23. Hirvonen A, Saarikoski ST, Linnainmaa K, Koskinen K, Husgafvel-Pursiainen K, Mattson K, Vainio H (1996). Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders. J Natl Cancer Inst 88:1853-1856.
24. Hishida A, Terakura S, Emi N, Yamamoto K, Murata M, Nishio K, Naoe T (2005). GSTT1 and GSTM1 deletions, NQO1 C609T polymorphism and risk of chronic myelogenous leukemia in Japanese. Asian Pac J Cancer Prev 6:251-255.
25. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M (1994). Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452-459.
26. Joseph T, Kusumakumary P, Chacko P, Abraham A, Radhakrishna Pillai M (2004). Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children. Pediatr Blood Cancer 43:560-567.
27. Kellerman G, Shaw CR, Luyten-Kellerman M (1973). Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N Engl J Med 289:934-937.
28. Khoury MJ (1996). From genes to public health: the applications of genetic technology in disease prevention. Genetics Working Group. Am J Public Health 86:1717-1722.
29. Krajinovic M, Labuda D, Richer C, Karimi S, Sinnett D (1999). Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 93:1496-1501.
30. Landi MT, Bertazzi PA, Shields PG, Clark G, Lucier GW, Garte SJ, et al. (1994). Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 4:242-246.
31. Lewis SJ, Cherry NM, Niven RM, Barber PV, Povey AC (2002). GSTM1, GSTT1 and GSTP1 polymorphisms and lung cancer risk. Cancer Lett 180:165-171.
32. Lu FJ, Wu YX, Gao YJ, Chen C, Jin TY, Jin XP, Xia ZL (2004). Genetic polymorphisms of GST gene and susceptibility to childhood leukemia. J Environ Occup Med 21:258-260.
33. Masson LF, Sharp L, Cotton SC, Little J (2005). Cytochrome P-450 1A1 gene polymorphisms and risk of breast cancer: a HuGE review. Am J Epidemiol 161:901-915.
34. Medeiros R, Vasconcelos A, Costa S, Pinto D, Ferreira P, Lobo F, et al. (2004). Metabolic susceptibility genes and prostate cancer risk in a southern European population: the role of glutathione S-transferases GSTM1, GSTM3, and GSTT1 genetic polymorphisms. Prostate 58:414-420.
35. Miller DP, Liu G, De Vivo I, Lynch TJ, Wain JC, Su L, Christiani DC (2002). Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. Cancer Res 62:2819-2823.
36. Naoe T, Takeyama K, Yokozawa T, Kiyoi H, Seto M, Uike N, et al. (2000). Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 6:4091-4095.
37. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, et al. (1994). Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 300 (Pt 1):271-276.
38. Peterson DD, McKinney CE, Ikeya K, Smith HH, Bale AE, McBride OW, Nebert DW (1991). Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet 48:720-725.
39. Roberts-Thomson IC, Butler WJ, Ryan P (1999). Meat, metabolic genotypes and risk for colorectal cancer. Eur J Cancer Prev 8:207-211.
40. Roddam PL, Rollinson S, Kane E, Roman E, Moorman A, Cartwright R, Morgan GJ (2000). Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. Pharmacogenetics 10:605-615.
41. Rodriguez-Antona C, Ingelman-Sundberg M (2006). Cytochrome P450 pharmacogenetics and cancer. Oncogene 25:1679-1691.
42. Rollinson S, Roddam P, Kane E, Roman E, Cartwright R, Jack A (2000). Polymorphic variation within the glutathione S-transferase genes and risk of adult acute leukaemia. Carcinogenesis 21:43-47.
43. Saadat M (2006). Genetic polymorphisms of glutathione S-transferase T1 (GSTT1) and susceptibility to gastric cancer: a meta-analysis. Cancer Sci 97:505-509.
44. Sim SC, Ingelman-Sundberg M (2006). The human cytochrome P450 Allele Nomenclature Committee Web site: submission criteria, procedures, and objectives. Methods Mol Biol 320:183-191.
45. Sinnett D, Krajinovic M, Labuda D (2000). Genetic susceptibility to childhood acute lymphoblastic leukemia. Leuk Lymphoma 38:447-462.
46. Sinnett D, N'Diaye N, Labuda D, Krajinovic M (2006). Genetic determinants of childhood leukemia. Bull Cancer 93:857-865.
47. Soya SS, Padmaja N, Adithan C (2005). Genetic polymorphisms of CYP2E1 and GSTP1 in a South Indian population-comparison with North Indians, Caucasians and Chinese. Asian Pac J Cancer Prev 6:315-319.
48. Spitz MR, Bondy ML (1993). Genetic susceptibility to cancer. Cancer 72 (Suppl 3):991-995.
49. Strange RC, Matharoo B, Faulder GC, Jones P, Cotton W, Elder JB, Deakin M (1991). The human glutathione S-transferases: a case-control study of the incidence of the GST1 0 phenotype in patients with adenocarcinoma. Carcinogenesis 12:25-28.
50. Sugimura T, Kumimoto H, Tohnai I, Fukui T, Matsuo K, Tsurusako S (2006). Gene-environment interaction involved in oral carcinogenesis: molecular epidemiological study for metabolic and DNA repair gene polymorphisms. J Oral Pathol Med 35:11-18.
51. Thuerauf N, Lunkenheimer J (2006). The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants. Eur Arch Psychiatry Clin Neurosci 256:287-293.
52. Voso MT, D'Alo F, Gumiero D, Guidi F, Hohaus S, Leone G (2005). The CYP1A1*2a allele is an independent prognostic factor for acute myeloid leukemia. Haematologica 90:982-984.
53. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML (1993). Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 53:410-418.
54. Wedding U, Bokemeyer C, Meran JG (2003). Elderly patients with acute myeloid leukemia: characteristics in biology, patients, and treatment. Med Klin (Munich) 98:193-207.
55. Whyatt RM, Bell DA, Jedrychowski W, Santella RM, Garte SJ, Cosma G, et al. (1998). Polycyclic aromatic hydrocarbon-DNA adducts in human placenta and modulation by CYP1A1 induction and genotype. Carcinogenesis 19:1389-1392.
56. Wilson VL, Weston A, Manchester DK, Trivers GE, Roberts DW, Kadlubar FF, et al. (1989). Alkyl and aryl carcinogen adducts detected in human peripheral lung. Carcinogenesis 10:2149-2153.
57. Yang J, Wu HF, Zhang W, Gu M, Hua LX, Sui YG, et al. (2006). Polymorphisms of metabolic enzyme genes, living habits and prostate cancer susceptibility. Front Biosci 11 (Suppl 1):2052-2060.
58. Yokoi T, Kamataki T (1998). Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese. Pharm Res 15:517-524.
59. Yuille M, Condie A, Hudson C, Kote-Jarai Z, Stone E, Eeles R (2002). Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia. Blood 99:4216-4218.
60. Zanger UM, Raimundo S, Eichelbaum M (2004). Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369:23-37.
61. Zubowska M, Zielinska E, Zmyslowska A, Bodalski J (2004). Increased frequency of A-G transition at exon 5 of GSTP1 as a genetic risk factor for acute childhood leukaemia. Med Wieku Rozwoj 8 (2 Pt 1):245-357.